Production (Stage)
Amicus Therapeutics, Inc.
FOLD
$6.22
-$0.04-0.64%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.45% | 30.09% | 36.73% | 34.04% | 27.97% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.45% | 30.09% | 36.73% | 34.04% | 27.97% |
| Cost of Revenue | -13.78% | 31.01% | 33.51% | 23.56% | 95.43% |
| Gross Profit | 17.26% | 29.99% | 37.07% | 35.16% | 22.07% |
| SG&A Expenses | 4.31% | 23.39% | 14.40% | 12.46% | 19.03% |
| Depreciation & Amortization | -14.72% | -6.46% | -2.60% | -1.09% | 71.36% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.85% | 12.60% | -1.53% | -0.17% | 6.81% |
| Operating Income | 63.31% | 532.58% | 265.04% | 186.07% | 42.02% |
| Income Before Tax | 58.60% | 125.06% | 127.46% | 100.27% | 18.11% |
| Income Tax Expenses | -24.71% | -411.73% | 532.03% | 482.14% | 1,785.02% |
| Earnings from Continuing Operations | 55.21% | 143.55% | 68.81% | 63.69% | 8.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 55.21% | 143.55% | 68.81% | 63.69% | 8.53% |
| EBIT | 63.31% | 532.58% | 265.04% | 186.07% | 42.02% |
| EBITDA | 68.68% | 1,292.85% | 310.72% | 212.95% | 45.96% |
| EPS Basic | 55.88% | 142.76% | 69.73% | 65.00% | 12.05% |
| Normalized Basic EPS | 52.65% | 144.02% | 142.50% | 100.24% | 31.78% |
| EPS Diluted | 55.88% | 142.76% | 69.73% | 65.00% | 12.05% |
| Normalized Diluted EPS | 52.65% | 144.02% | 142.50% | 100.24% | 31.78% |
| Average Basic Shares Outstanding | 1.58% | 1.81% | 3.02% | 3.75% | 3.97% |
| Average Diluted Shares Outstanding | 1.58% | 1.81% | 3.02% | 3.75% | 3.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |